Medpace Holdings, Inc. (MEDP) EPS CAGR:19.77%(TTM)
EPS CAGR uses precomputed diluted earnings history where available.
Over longer horizons, Medpace Holdings, Inc.'s EPS CAGR averages 27.36% over 3 years and 30.90% over 5 years.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. EPS (Earnings Per Share) CAGR measures how Medpace Holdings, Inc.'s earnings per share have grown. This is a key metric for valuation and reflects profitability on a per-share basis.
MEDP EPS CAGR Chart
Medpace Holdings, Inc. (MEDP)
MEDP Quarterly EPS Growth (YoY)
EPS growth vs the same quarter one year earlier, last 20 quarters.
MEDP EPS CAGR History
| Year | Start EPS | End EPS | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $13.06 | $15.64 | +$2.58 | +19.75% | +19.75% |
| 2024 | $9.20 | $13.06 | +$3.86 | +41.96% | +41.96% |
| 2023 | $7.57 | $9.20 | +$1.63 | +21.53% | +21.53% |
| 2022 | $5.06 | $7.57 | +$2.51 | +49.60% | +49.60% |
| 2021 | $4.07 | $5.06 | +$0.99 | +24.32% | +24.32% |
| 2020 | $2.79 | $4.07 | +$1.28 | +45.88% | +45.88% |
| 2019 | $2.05 | $2.79 | +$0.74 | +36.10% | +36.10% |
| 2018 | $1.00 | $2.05 | +$1.05 | +105.00% | +105.00% |
| 2017 | $0.38 | $1.00 | +$0.62 | +163.16% | +163.16% |
| 2016 | $-0.28 | $0.38 | +$0.66 | N/A | N/A |
| 2015 | $-0.53 | $-0.28 | +$0.25 | N/A | N/A |
| 2014 | $1.33 | $-0.53 | $-1.86 | -139.85% | N/A |
Quarterly EPS: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2026 | $4.35 | -9.0% | +15.4% |
| Q4 2025 | $4.78 | +21.0% | +26.5% |
| Q3 2025 | $3.95 | +25.0% | +27.0% |
| Q2 2025 | $3.16 | -16.2% | +10.9% |
| Q1 2025 | $3.77 | -0.3% | +13.6% |
| Q4 2024 | $3.78 | +21.5% | +48.2% |
| Q3 2024 | $3.11 | +9.1% | +35.2% |
| Q2 2024 | $2.85 | -14.2% | +42.5% |
| Q1 2024 | $3.32 | +30.2% | +41.3% |
| Q4 2023 | $2.55 | +10.9% | +15.9% |
| Q3 2023 | $2.30 | +15.0% | +8.0% |
| Q2 2023 | $2.00 | -14.9% | +31.6% |
| Q1 2023 | $2.35 | +6.8% | +34.3% |
| Q4 2022 | $2.20 | +3.3% | +58.3% |
| Q3 2022 | $2.13 | +40.1% | +57.8% |
| Q2 2022 | $1.52 | -13.1% | +36.9% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About Medpace Holdings, Inc.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- August James Troendle